🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Ardelyx, Inc. ARDX R2K

Healthcare · Biotechnology · United States
https://www.ardelyx.com
Company Profile ↓
$5.16
+11.93% 1Y
Mkt Cap$1.27B
P/E-21.50
P/B9.45
52W High$7.99
52W Low$4.22
Book Value$0.60
EPS (TTM)$-0.24

Company Overview

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 98.4% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $407.32M (+22.1% YoY); net profit $-61.60M.
  • Trailing 12 Months Year-on-year growth — revenue +27.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 98.4%, profit CAGR 2.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:98.40%
1 Year:27.50%

Compounded Profit Growth

5 Years:2.78%
1 Year:-

Stock Price Performance

1 Year:+11.93%
6 Months:-33.33%
3 Months:-18.48%
1 Month:-10.88%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 25% of range
$4.22 $7.99
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • Death Cross10d ago
  • RSI (14)36.93 · Neutral
Price Performance
1M-10.88%
3M-18.48%
6M-33.33%
1Y+11.93%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 98.4% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 35.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-21.50
Industry PE
25.41
Forward P/E
10.02
PEG Ratio
-
Book Value
$0.60
Price to Book
9.45
P/S
3.29
EV/EBITDA
-41.17
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
98.40%
Profit 5Y
2.78%
Revenue (YoY)
27.50%
Earnings (YoY)
-

Profitability & Returns

ROCE
-7.80%
ROE
-39.46%
ROA
-5.11%
Profit Margin
-13.58%
Op Margin
-34.71%
Gross Margin
74.56%
EPS (Latest Qtr)
$-0.15
EPS (TTM)
$-0.24

Balance Sheet & Liquidity

Debt/Equity
1.58
Quick Ratio
2.93
Current Ratio
3.48
Debt
$234.13M
Total Assets
$504.51M
Current Assets
$381.87M
Working Capital
$293.71M

Ownership

Promoter Holding
3.28%
Chg in Prom Hold
0.09%
FII / Inst Holding
70.66%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
$1.27B
Total Revenue (TTM)
$427.68M
EBITDA
$-34.05M
Free Cash Flow
$86.38K
Operating Cash Flow
$-36.26M
Shares Outstanding
247.03M
Gross Margin
74.56%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ARDX Ardelyx, Inc. R2K 5.16 -21.50 $1.27B 0.00% -7.80% -39.46% 98.40% 2.78%
2 LLY Eli Lilly and Company SPX 1,152.54 41.02 $1.03T 0.61% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 253.85 29.45 $611.07B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.78 119.40 $432.48B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 425.19 32.02 $386.13B 2.27% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 120.78 34.02 $298.31B 2.86% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 164.50 24.81 $255.12B 1.77% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 534.07 29.33 $198.47B 0.40% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 355.25 24.69 $191.73B 2.84% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -----------2.32M30.00K172.00K85.00K-18.00K3.01M2.25M1.21M1.84M2.71M1.81M6.58M1.31M1.17M468.00K2.53M4.99M11.37M22.33M56.39M46.02M73.22M98.24M74.11M97.66M110.33M125.22M94.47M
Cost of Revenue -----------------------------------12.30M12.40M3.98M10.85M4.81M
Gross Profit ----------33.60M1.86M30.00K170.00K85.00K-18.00K2.41M2.25M----------------61.81M85.26M106.35M114.37M89.66M
Operating Expenses -----------------------------------98.16M99.65M101.68M109.27M122.45M
Operating Income 9.06M-18.08M--23.53M-28.69M-29.20M--28.43M-26.42M-21.23M--17.68M-22.15M-23.73M--25.50M-24.83M-22.09M--21.77M-24.21M-17.16M--32.01M-44.83M-42.24M-27.81M-26.21M-21.88M-26.06M-16.62M7.40M-24.68M-13.63M2.23M-36.35M-14.39M4.67M5.10M-32.79M
EBITDA ------------------------------------33.42M-11.87M8.02M8.10M-29.77M
Interest Expense -----------------------------------6.26M6.58M7.98M7.58M6.92M
Pretax Income ------------------------------------40.28M-19.08M-867.00K-400.00K-37.60M
Tax Provision -----------------------------------859.00K1.00K102.00K7.00K8.00K
Net Income 9.01M-18.13M-17.00M-23.47M-28.61M-29.03M-31.28M-28.01M-25.72M-20.72M10.11M-17.02M-22.29M-24.13M-27.86M-26.14M-25.47M-23.54M-19.79M-22.37M-24.96M-18.11M-28.88M-33.16M-45.19M-43.59M-28.07M-26.94M-22.89M-26.77M-17.12M6.63M-26.52M-16.45M-809.00K-41.14M-19.08M-969.00K-407.00K-37.60M
Diluted EPS 0.42-0.70-0.65--0.83---0.59-0.54-0.440.21---------0.25-0.28-0.20--0.34-0.45-0.42-0.21-0.19-0.14-0.13-0.080.03-0.11-0.070.00-0.17-0.080.000.00-0.15
R&D Expense 6.20M14.71M-19.25M23.84M24.86M-22.39M20.57M15.37M-13.35M16.05M17.94M-20.38M19.48M17.58M-15.84M18.86M12.24M-20.46M26.02M23.70M8.85M9.74M7.47M9.09M8.28M8.64M10.58M12.76M15.31M14.94M15.67M18.07M-20.19M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 5.41M28.93M31.62M24.03M-42.00M2.61M5.28M7.57M-52.16M124.46M333.62M407.32M
Cost of Revenue ----------4.12M17.80M50.56M39.54M
Gross Profit ---24.03M-33.60M2.14M4.68M--48.04M106.66M283.06M367.78M
Operating Expenses ----------111.80M169.94M311.01M408.76M
Operating Income -8.80M-2.87M-1.56M-29.39M-112.89M-65.11M-90.95M-91.26M-90.78M--63.76M-63.28M-27.95M-40.98M
EBITDA -----------60.98M-55.35M-16.71M-29.17M
Interest Expense ----------5.07M8.87M20.09M28.40M
Pretax Income -----------67.20M-65.52M-38.87M-60.63M
Tax Provision ----------8.00K547.00K266.00K969.00K
Net Income -9.79M-6.56M-3.21M-29.62M-112.39M-64.34M-91.30M-94.94M-94.31M--67.21M-66.07M-39.14M-61.60M
Diluted EPS --------1.47-1.05--0.42-0.30-0.17-0.26
R&D Expense 10.18M28.09M25.90M39.88M94.16M75.48M69.37M71.68M65.05M91.14M35.20M35.54M52.32M71.53M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Jan 2018Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --42.90M113.41M116.95M213.13M157.90M-183.33M259.78M201.56M-190.07M297.58M435.75M501.60M
Current Assets ------------153.60M246.11M356.45M382.32M
Cash & Equivalents 10.78M32.90M34.44M107.29M107.00M74.60M75.38M-78.77M181.13M91.03M-96.14M21.47M64.93M68.00M
Inventory ------------3.28M12.45M21.17M17.73M
Receivables ------------7.73M22.03M57.70M71.85M
Total Liabilities --50.23M52.73M8.04M19.98M18.59M-67.52M73.13M75.45M-91.74M130.76M262.46M334.65M
Current Liabilities --17.14M21.54M7.72M19.20M17.87M1.00M17.73M22.22M28.42M-65.60M50.39M77.83M88.61M
Long Term Debt --------51.98M50.01M50.79M--49.82M150.85M202.83M
Total Debt ------------36.46M55.98M153.44M207.95M
Total Equity -48.26M-57.39M-63.48M60.68M108.90M193.15M139.31M-115.81M186.66M126.11M-98.33M166.82M173.29M166.95M
Shares Outstanding ------------198.58M232.45M238.02M244.35M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ----71.84M-92.53M-65.19M-70.27M-76.48M-81.44M--70.04M-89.72M-44.81M-42.48M
Investing Cash Flow ----3.45M-131.08M65.29M-29.89M23.37M-31.44M-18.41M-131.25M-18.32M-8.96M
Financing Cash Flow ---75.01M191.20M685.00K103.55M155.48M22.78M-75.34M146.29M106.59M54.51M
Capital Expenditure -128.00K-278.00K-1.86M-3.45M-4.87M-2.35M-311.00K-325.00K-324.00K--55.00K-344.00K-1.01M-1.49M
Free Cash Flow ----75.29M-97.40M-67.55M-70.58M-76.81M-81.76M--70.10M-90.06M-45.82M-43.98M
Net Change in Cash ----------23.71M-74.67M43.46M3.07M
Share Buybacks 20.00K2.00K2.00K-----------

Ratios (Annual)

Figures in %.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---100.0%-80.0%82.1%88.6%--92.1%85.7%84.8%90.3%
Operating Margin % -162.8%-9.9%-4.9%-122.3%--155.0%-3,488.6%-1,728.1%-1,199.0%--122.2%-50.8%-8.4%-10.1%
Net Margin % -180.9%-22.7%-10.2%-123.3%--153.2%-3,502.0%-1,797.8%-1,245.7%--128.9%-53.1%-11.7%-15.1%
ROE % 17.0%10.3%-5.3%-27.2%-58.2%-46.2%-78.8%-50.9%-74.8%--68.3%-39.6%-22.6%-36.9%
ROCE % --11.1%-1.7%-26.9%-58.2%-46.5%-54.9%-38.4%-52.4%--51.2%-25.6%-7.8%-9.9%

Shareholding Pattern

Insiders
3.28%
Institutions
70.66%
Public Float
73.05%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.57% 21.16M $111.11M
2 Millennium Management Llc 7.22% 17.84M $93.67M
3 State Street Corporation 5.51% 13.60M $71.42M
4 Vanguard Capital Management LLC 4.20% 10.37M $54.42M
5 Janus Henderson Group PLC 3.39% 8.37M $43.95M
6 Nomura Asset Management International Inc 3.31% 8.17M $42.89M
7 Vanguard Portfolio Management LLC 2.70% 6.66M $34.97M
8 Geode Capital Management, LLC 2.43% 6.01M $31.54M
9 Nuveen, LLC 2.12% 5.23M $27.48M
10 Two Sigma Investments, LP 1.73% 4.27M $22.44M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ARDX

Yahoo Finance Fri, 26 Jun 2026

ARDX Stock Tumbles As Xphozah Loses Final Medicare Reimbursement Battle

The U.S. Court of Appeals for the D.C. Circuit said federal law prevents judges from reviewing Medicare’s decision to include certain kidney drugs in the dialysis payment bundle.

Yahoo Finance Wed, 24 Jun 2026

Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?

Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.…

Yahoo Finance ue, 23 Jun 2026

Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction

This biotech specializing in gastrointestinal and cardiorenal therapies reported a notable insider sale following strong 1-year returns.

Yahoo Finance ue, 23 Jun 2026

What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline?

Ardelyx, Inc. (NASDAQ:ARDX) is among the best low priced stocks to get rich in 2026. On June 16, Ladenburg started coverage on Ardelyx, Inc. (NASDAQ:ARDX) with a Buy rating and a price target of $16. According to TheFly, the company is curr…

Yahoo Finance Fri, 12 Jun 2026

Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility

Ardelyx stock snapshot and recent performance Ardelyx (ARDX) has been drawing more attention after recent share price moves, with the stock up 3.2% over the past day and 7.2% over the past week, despite being down 12.4% over the past month.…

Yahoo Finance hu, 04 Jun 2026

Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach

Ardelyx (NASDAQ:ARDX) executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning…

ARDX — Frequently Asked Questions

What is the current share price of Ardelyx, Inc. (ARDX)?

As of 2026-07-14 21:23 PDT, Ardelyx, Inc. (ARDX) trades at $5.16 on NasdaqGM. Its 52-week range is $4.22 to $7.99.

What is the market capitalisation of ARDX?

Ardelyx, Inc. (ARDX) has a market capitalisation of $1.27B on NasdaqGM.

What is the P/E ratio of ARDX?

ARDX trades at a trailing price-to-earnings (P/E) ratio of -21.50. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 9.45.

What is the return on equity (ROE) of ARDX?

ARDX has a return on equity (ROE) of -39.46%. Its return on capital employed (ROCE) is -7.80%.

Is ARDX a good stock to buy?

This page provides a data-driven analysis of Ardelyx, Inc. (ARDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space